Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow (HROW) announced a definitive agreement to acquire TYRVAYA (varenicline) nasal spray 0.03 mg from Viatris. TYRVAYA is approved for dry eye disease (DED) signs and symptoms in the U.S. (and also authorized in China and Taiwan), with additional country marketing approvals pending. The deal modestly improves Harrow’s ophthalmic product portfolio and could be a positive read-through for future revenue ramp.

Analysis

The strategic value here is less about the asset itself and more about HROW’s ability to monetize an ophthalmology sales channel that already has physician mindshare. If TYRVAYA is layered onto an existing specialty footprint, the revenue uplift can come with disproportionate operating leverage because the incremental selling cost should be lower than building a standalone launch from scratch. The market will likely reward evidence of faster script conversion, not the announcement alone.

The main loser is not VTRS so much as any dry-eye incumbent that relies on fragmented detailing economics, especially BHC and other eye-care players with overlapping prescriber bases. The second-order effect is potential share capture through bundling and better access to retina/cornea specialists, but that only matters if persistence is decent; dry-eye therapies often look good in launch metrics and then fade on refill behavior. Over the next 1-3 months, terms of consideration and financing mix will matter more than the press release.

The contrarian miss is that this could be an asset-transfer at a fair price rather than genuine value creation. If HROW overpays, the market will see a higher-leverage roll-up with modest organic upside; if it underpays and can cross-sell effectively, this becomes a small but real multiple expansion story. Falsifiers are simple: weak post-close prescriptions, margin dilution, or leverage moving to an uncomfortable level; for VTRS, no meaningful rerating should occur unless proceeds are clearly directed to debt reduction.

Key Decisions for Investors

• Watchlist, not blind buy: wait for disclosed purchase price and financing. If HROW trades down >5% on leverage fears but terms imply limited dilution, use that weakness to build a 1-3 month long with a stop if pro forma net leverage looks >4x.
• Relative-value idea: long HROW / short BHC for a 1-3 month window if HROW’s channel leverage can accelerate dry-eye scripts. Target 10-15% relative outperformance; exit if HROW financing is equity-heavy or BHC posts better prescription momentum.
• Do not short VTRS on this headline alone. Treat any move as a potential debt-management positive; only reconsider if management confirms sale proceeds will be redeployed into low-return acquisitions instead of deleveraging.
• Use a small HROW call-spread only after deal terms are public and if implied dilution looks manageable. The options payoff is best if the market initially discounts integration but re-rates on 1-2 quarters of script data.
• Set a catalyst alert for the first post-close earnings call: if TYRVAYA does not show clear sequential prescription growth or gross margin accretion, the thesis weakens and the stock should be de-risked.